Sutro Biopharma, Inc.

66 articles with Sutro Biopharma, Inc.

• Sutro Biopharma Announces Presentation of STRO-002 for the Potential Treatment of Ovarian and Endometrial Cancer at the 2019 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference

  10/16/2019

  Sutro discovered and manufactures STRO-002 using its proprietary XpressCF+™ cell-free protein synthesis technology.

• Sutro Biopharma to Receive Milestone Payment for Novel Bispecific Antibody Drug Conjugate Targeting Solid Tumors

  10/8/2019

   Merck KGaA, Darmstadt, Germany Designates Undisclosed Bispecific ADC as Clinical Development Candidate

• Sutro Biopharma to Present at the H.C. Wainwright 21st Annual Healthcare Conference

  9/4/2019

  Sutro Biopharma, Inc. announced that Bill Newell, CEO of Sutro Biopharma, will present a corporate overview at the H.C. Wainwright 21st Annual Healthcare Conference on Tuesday, Sept. 10, 2019, at 11:40 AM EDT, in New York City.

• Sutro Biopharma Reports Second Quarter 2019 Financial Results and Recent Business Highlights and Developments

  8/14/2019

  Sutro Biopharma, Inc. reported its financial results for the three and six months ended June 30, 2019.

• Sutro Biopharma to Present at the 2019 Wedbush PacGrow Healthcare Conference

  8/8/2019

  Sutro Biopharma, Inc. announced that its Chief Business Officer, Stephen Worsley, will present at the 2019 Wedbush PacGrow Healthcare Conference on Tuesday, Aug. 13 at 1:20 p.m. EDT in New York City.

• Sutro Biopharma Appoints Biopharma Veteran Connie Matsui as Board Chair

  6/24/2019

  Former Biogen Idec executive to bring additional strategic expertise to Sutro's Board

• Sutro Biopharma to Present at the JMP Securities Life Sciences Conference

  6/18/2019

  Sutro Biopharma, Inc. announced that Steve Worsley, Chief Business Officer, will present a company overview at the JMP Securities Life Sciences Conference on Thursday, June 20 at 12:30 p.m. ET at the St.

• Sutro Biopharma Announces Encouraging Interim Phase 1 Safety Data on a Potential First-in-Class Antibody-Drug Conjugate STRO-001 for the Treatment of B-cell Malignancies at the European Hematology Association Congress

  6/15/2019

  Interim results show STRO-001 was generally well tolerated and anti-tumor activity was observed in two patients with recurrent diffuse large B-cell lymphoma (DLBCL)

• Sutro Biopharma Announces Presentation at the 2019 European Hematology Association Congress

  5/16/2019

  Sutro Biopharma, Inc. announced that the company will present at the upcoming European Hematology Association Congress being held June 13-16, 2019, in Amsterdam.

• Sutro Biopharma Reports First Quarter 2019 Financial Results and Recent Business Highlights and Developments

  5/15/2019

  Sutro Biopharma, Inc. reported its financial results for the quarter ended March 31, 2019.

• Sutro Biopharma to Present at the 18th Annual Needham Healthcare Conference

  4/4/2019

  Sutro Biopharma, Inc. announced that Bill Newell, Chief Executive Officer, will present at the 18th Annual Needham Healthcare Conference on Tuesday, April 9 at 4:50 p.m. ET at the Westin Grand Central Hotel in New York.

• 

  Changing the Public’s Perception of the Biopharma Industry

  4/3/2019

  Public perception of the industry can be a bit confusing. Life Science Leader recently pulled together several biopharma executives for a round table discussion of the biopharma industry’s public perception—generally bad—and what might be able to do about it.

• Sutro Biopharma Reports Full Year 2018 Financial Results and Recent Business Highlights and Developments

  4/1/2019

  STRO-001 Ongoing Phase 1 Trial in Myeloma and Lymphoma with Initial Safety Data Expected Mid-2019

• Sutro Biopharma Initiates Phase I Clinical Trial of STRO-002 for the Treatment of Ovarian and Endometrial Cancers

  3/15/2019

  Sutro Biopharma, Inc. (NASDAQ: STRO) today announced that it has dosed the first patient in a Phase I study of STRO-002, an anti-folate receptor alpha (FoIRα) antibody-drug conjugate (ADC), in patients with ovarian and endometrial cancers.

• Sutro Biopharma to Present at the Cowen and Company 39th Annual Health Care Conference

  3/5/2019

  Sutro Biopharma, Inc. announced that Bill Newell, Chief Executive Officer, will present at the Cowen and Company 39th Annual Health Care Conference on Monday, March 11 at 2:50 p.m. ET at the Marriott Copley Place in Boston.

• Sutro Biopharma Expands Leadership Team with Appointment of Vice President of Chemistry

  1/29/2019

  - Veteran Pfizer researcher Andreas Maderna, Ph.D., joins the company

• Sutro to Present at 37th Annual J.P. Morgan Healthcare Conference

  1/3/2019

  Sutro Biopharma, Inc. today announced that Bill Newell, Chief Executive Officer, will present at the 37th Annual J.P. Morgan Healthcare Conference on Thursday, Jan. 10, 2019 at 11:30 a.m. PT / 2:30 p.m. ET at the Westin St. Francis Hotel in San Francisco.

• Sutro Achieves $10 Million Milestone Payment from Celgene

  12/19/2018

  Sutro develops successful spray drying technology marking a major advancement in commercial-scale manufacturing capabilities

• Sutro to Participate in the 30th Annual Piper Jaffray Healthcare Conference

  11/26/2018

  Sutro Biopharma, Inc. will present at the 30th Annual Piper Jaffray Healthcare Conference.

• Sutro Biopharma Reports Third Quarter 2018 Financial Results

  11/14/2018

  STRO-001 Received Orphan Drug Designation for Treatment of Multiple Myeloma